The fracture and osteoporosis clinic: 1-year results and 3-month compliance

Bone

Volumn 40, Issue 6, 2007, Pages 1643-1649

  Blonk, Marion C ^a   Erdtsieck, Ronald J ^b   Wernekinck, Marian G A ^c   Schoon, Erik J ^a  

^a CATHARINA HOSPITAL   (Netherlands)

^b MÁXIMA MEDICAL CENTER   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Compliance; Fracture; Osteoporosis; Prevalence

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; RALOXIFENE; VITAMIN D;

ADULT; AGED; ARTICLE; CONSTIPATION; DIAGNOSTIC PROCEDURE; DIARRHEA; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HAND FRACTURE; HEADACHE; HUMAN; LUMBAR SPINAL CORD; MAJOR CLINICAL STUDY; MALE; NAUSEA; NURSE; OSTEOPOROSIS; PATIENT ASSESSMENT; PRESCRIPTION; QUESTIONNAIRE; RADIODIAGNOSIS; SELF REPORT; SPINE RADIOGRAPHY; STOMACH DISCOMFORT; THORACIC SPINAL CORD; VITAMIN SUPPLEMENTATION; WRIST FRACTURE; XEROSTOMIA;

AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; BONE DENSITY; DENSITOMETRY, X-RAY; FEMALE; FRACTURES, BONE; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; NETHERLANDS; OSTEOPOROSIS; PATIENT COMPLIANCE; PREVALENCE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; THORACIC VERTEBRAE; TIME FACTORS;

EID: 34248563740     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.01.023     Document Type: Article

References (24)

1. Klotzbuercher C.M., Ross Ph.D., Landsman P.B., Abbott T., and Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J. Bone Miner. Res. 15 (2000) 721-734
2. Staa van T.P., Leufkens H.G.M., and Cooper C. Does a fracture at one site predict later fractures at other sites? A British Cohort Study. Osteoporos. Int. 13 (2002) 624-629
3. Schuit S.C.E., Klift van der M., Weel A.E.A.M., et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34 (2004) 195-202
4. Johnell O., Kanis J.A., Oden A., Sernbo I., Redlund-Johnell I., Pettterson C., et al. Fracture risk following an osteoporotic fracture. Osteoporos. Int. 15 (2004) 175-179
5. Helden van S., Cals J., Kessels F., et al. Risk of new fractures within 2 years following a fracture. Osteoporos. Int. 17 (2006) 348-354
6. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1996) 1535-1541
7. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture intervention Trial. JAMA 280 (1998) 2077-2082
8. World Health Organization. Assessment of fracture risk and application to screening for postmenopausal osteoporosis. WHO Technical Report Series. WHO, Geneva 1994.
9. Heaney R.P., Zizic T.M., Fogelman I., et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos. Int. 13 (2002) 501-505
10. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med. 344 (2001) 333-340
11. CBO. Tweede herziene Richtlijn Osteoporose (2002), CBO, Utrecht
12. Elders P.J.M., Leusink G.L., Graafmans W.C., et al. NHG-standard osteoporose. Huisarts Wet. 48 11 (2005) 559-570
13. McLellan A.R., Gallacher S.J., Fraser M., and McQuillian C. The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos. Int. 14 (2003) 1028-1034
14. Mc Lellan A.R. Identification and treatment of osteoporosis in fractures. Curr. Rheumatol. Rep. 5 (2003) 57-64
15. Solomon D.H., Avorn J., Katz J.N., et al. Compliance with osteoporosis medications. Arch. Intern. Med. 165 (2005) 2414-2419
16. Panneman M.J.M., Lips P., Sen S.S., and Herings R.M.C. Undertreatment with anti-osteoporotic drugs after hospitalization for a fracture. Osteoporos. Int. 15 (2004) 120-124
17. Tosteson A.N.A., Grove M.R., Hammond C.S., et al. Early discontinuation of treatment for osteoporosis. Am. J. Med. 115 (2003) 209-216
18. Caro J.J., Ishak K.J., Huybrechts K.F., Raggio G., and Naujoks Ch. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos. Int. 15 (2004) 1003-1008
19. Lo J.C., Pressman A.R., Omar M.A., and Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos. Int. 17 6 (2006) 922-928
20. Cramer J.A., Amonkar M.M., Hebborn A., and Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr. Med. Res. Opin. 21 (2005) 1453-1460
21. Schnitzer T. Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin. Exp. Res. 12 (2000) 1-12
22. Rossini M., Bianchi G., Di Munno O., et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos. Int. 17 6 (2006) 914-921
23. Lips P., Ginkel van F.C., Jongen M.J., Rubertus F., Vijgh van der W.J., and Netelenbos J.C. Determinants of vitamin D status in patients with hip fracture and in elderly control subjects. Am. J. Clin. Nutr. 46 (1987) 1005-1010
24. Cuddihy M.T., Amadio P.C., Gabriel S.E., et al. A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture. Osteoporos. Int. 15 (2004) 695-700